Zhang J-j, Sun W-j, Huang Z-x, Chen S-l, Zhong Y-p, Hu Y et al (2014) Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term study. World J Surg Oncol 12:1–4

Article  Google Scholar 

Chilkulwar A, Miller A, Mewawalla P, Berteotti G, Kaminsky A, Sadhashiv S et al (2016) High serum free light chain concentration (> 1000 mg/dl) at the time of relapse to predict poor prognosis in multiple myeloma. J Clin Oncol 34(15suppl):8064

Article  Google Scholar 

Singh G, Xu H (2021) Light chain predominant intact immunoglobulin monoclonal gammopathy disorders: shorter survival in light chain predominant multiple myelomas. Lab Med 52(4):390–398

Article  PubMed  Google Scholar 

Benson R, Nair SG, Narayanan G (2020) Early normalization of Free Light Chains predicts better outcomes in patients with multiple myeloma. Int J hematology-oncology stem cell Res 14(4):226–231

Google Scholar 

Huang ZQ, Kirk KA, Connelly KG, Sanders PW (1993) Bence Jones proteins bind to a common peptide segment of Tamm-Horsfall glycoprotein to promote heterotypic aggregation. J Clin Investig 92(6):2975–2983

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leung N, Rajkumar SV (2023) Multiple myeloma with acute light chain cast nephropathy. Blood Cancer J 13(1):46

Article  PubMed  PubMed Central  Google Scholar 

Chilkulwar A, Mewawalla P, Miller A, Berteotti G, Sahovic E, Lister J (2016) Serum free light chain concentration (> 1000 mg/dl) at diagnosis and at Relapse predicts for very poor prognosis in multiple myeloma. Blood 128(22):5698

Article  Google Scholar 

El Naggar AA, El-Naggar M, Mokhamer el H, Avad MW (2015) Prognostic value of serum free light chain in multiple myeloma. Egypt J Immunol 22(1):69–78

PubMed  Google Scholar 

Haynes RJ, Read S, Collins GP, Darby SC, Winearls CG (2010) Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrology, dialysis, transplantation: official publication of the European dialysis and transplant association. Eur Ren Association 25(2):419–426

Google Scholar 

Tsakiris DJ, Stel VS, Finne P, Fraser E, Heaf J, de Meester J et al (2010) Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study. Nephrology, dialysis, transplantation: official publication of the European dialysis and transplant association. Eur Ren Association 25(4):1200–1206

Google Scholar 

Kumar S, Dispenzieri A, Larson D, Colby C, Kyle R, Gertz M et al (2008) Normalization of the serum free light chain (FLC) ratio is Associated with Superior overall survival among Myeloma patients Achieving Immunofixation negative state: results support incorporation of serum FLC ratio in stringent CR definition. Blood 112(11):1692

Article  Google Scholar 

Herrera GA, Joseph L, Gu X, Hough A, Barlogie B (2004) Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med 128(8):875–879

Article  PubMed  Google Scholar 

Dixit J, Malhotra P, Mehra N, Mathew A, Kumar L, Singh A et al (2024) Cost-effectiveness of novel agent regimens for transplant-eligible newly diagnosed multiple myeloma patients in India. Applied Health Econ Health Policy

Rajkumar SV (2022) Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 97(8):1086–1107

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dimopoulos MA, Merlini G, Bridoux F, Leung N, Mikhael J, Harrison SJ et al (2023) Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. Lancet Oncol 24(7):e293–e311

Article  PubMed  Google Scholar 

Lu S, Robyak K, Zhu Y (2023) The CKD-EPI 2021 equation and other Creatinine-based race-independent eGFR equations in chronic kidney disease diagnosis and staging. J Appl Lab Med 8(5):952–961

Article  PubMed  Google Scholar 

Martellosio JP, Leleu X, Roblot P, Martin M, Puyade M (2019) Free light chains assay: indications and methods. La Revue De Med Interne 40(5):297–305

Article  Google Scholar 

Rana R, Cockwell P, Drayson M, Cook M, Pratt G, Cairns DA et al (2020) Renal outcome in patients with newly diagnosed multiple myeloma: results from the UK NCRI Myeloma XI trial. Blood Adv 4(22):5836–5845

Article  CAS  PubMed  PubMed Central  Google Scholar 

Courant M, Orazio S, Monnereau A, Preterre J, Combe C, Rigothier C (2021) Incidence, prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma: a population-based registry. Nephrology, dialysis, transplantation: official publication of the European dialysis and transplant association. Eur Ren Association 36(3):482–490

CAS  Google Scholar 

Jian Y, Zhou H, Xie W, Ren Y, Zhang Z, Yang G et al (2022) Impact of dialysis dependence on survival for multiple myeloma patients with renal impairment: a multicenter retrospective study in China. Blood 140(Supplement 1):12635–12636

Article  Google Scholar 

Dimopoulos MA, Roussou M, Gavriatopoulou M, Fotiou D, Ziogas DC, Migkou M et al (2017) Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit. Blood Cancer J 7(6):e571–e

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martinez-Cordero H, Fuentes Lacouture MC, Von Glasenapp SA, Peña C, Riva E (2023) Renal failure in patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant in LATAM - on behalf of Gelamm. Blood 142(Supplement 1):3346

Article  Google Scholar 

Gonsalves WI, Leung N, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR et al (2015) Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer J 5(3):e296–e

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sakhuja V, Jha V, Varma S, Joshi K, Gupta KL, Sud K et al (2000) Renal involvement in multiple myeloma: a 10-year study. Ren Fail 22(4):465–477

Article  CAS  PubMed  Google Scholar 

Sharma R, Jain A, Jandial A, Lad D, Khadwal A, Prakash G et al (2022) Lack of renal recovery predicts poor survival in patients of multiple myeloma with renal impairment. Clin Lymphoma Myeloma Leuk 22(8):626–634

Article  PubMed  Google Scholar 

Balwani MR, Gumber MR, Shah PR, Kute VB, Patel HV, Engineer DP et al (2016) Clinical profile of kidney involvement preceding diagnosis of multiple myeloma; a single center experience. J Nephropharmacology 5(2):98–101

CAS  Google Scholar 

Yadav P, Sathick IJ, Leung N, Brown EE, Cook M, Sanders PW et al (2020) Serum free light chain level at diagnosis in myeloma cast nephropathy-a multicentre study. Blood Cancer J 10(3):28

Article  PubMed  PubMed Central  Google Scholar 

Yadav P, Cockwell P, Cook M, Pinney J, Giles H, Aung YS et al (2018) Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma. BMC Nephrol 19(1):178

Article  PubMed  PubMed Central  Google Scholar 

Terrades NR, Senin A, Azancot MA, Gironella M, Toapanta N, Bermejo S et al (2023) Role of light chain clearance in the recovery of renal function in multiple myeloma: another point of view. Clin Kidney J 16(6):1014–1021

Article  CAS  PubMed  PubMed Central  Google Scholar 

Royal V, Leung N, Troyanov S, Nasr SH, Écotière L, LeBlanc R et al (2020) Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study. Blood 135(21):1833–1846

Article  PubMed  PubMed Central  Google Scholar 

Konnur Md A, Gang S, Hegde U, Rajapurkar M, Patel H, Singhal S et al (2021) POS-487 a study of clinical profile and outcome analysis of patients with multiple myeloma and kidney disease in a tertiary care centre in west India. Kidney Int Rep 6(4):S211

Article  Google Scholar 

Yanamandra U, Sharma R, Shankar S, Yadav S, Kapoor R, Pramanik S et al (2021) Survival outcomes of newly diagnosed multiple myeloma at a tertiary care center in North India (IMAGe: 001A study). JCO Global Oncol 7:704–715

Article  Google Scholar 

Mrachacz H, Khoder N, Plötze M, Holzvogt B, Andrea M, Schliwa T et al (2015) Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine; prednisone and bortezomib (BPV). Clin Lymphoma Myeloma Leuk 15:e167–e8

Article  Google Scholar 

Heaney JL, Campbell JP, Griffin AE, Birtwistle J, Shemar M, Child JA et al (2017) Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests. Br J Haematol 178(2):220–230

Article  CAS  PubMed  Google Scholar 

Avivi I, Cohen YC, Joffe E, Benyamini N, Held-Kuznetsov V, Trestman S et al (2017) Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome. Hematol Oncol 35(4):734–740

Article  CAS  PubMed